Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de Daniel O'Day
Age : 56
Public asset : 9,388,479 USD
Country of residence : Unknown
Linked companies : Gilead Sciences, Inc. - Galapagos NV

Biography of Daniel O'Day 
Mr. Daniel P. O'Day is a Chairman & Chief Executive Officer at Gilead Sciences, Inc. He is on the Board of Directors at Galapagos NV, Flatiron Health, Inc., Pharmaceutical Manufacturers Association of America, Pharmaceutical Research & Manufacturers of America and Shanghai Roche Pharmaceuticals Ltd. Mr. O'Day was previously employed as a President & Chief Executive Officer by Roche Molecular Systems, Inc., a General Manager by Roche A/S Medicinalvarer OG Kemikalier, a Chief Operating Officer by Roche Diagnostics A/S, a Head-Business Unit, Arthritis & Respiratory by Roche Pharma Schweiz AG, a Chief Executive Officer by Roche Pharmaceuticals, Inc., a Head-Corporate Planning by Roche Diagnostics KK, and a CEO-Roche Pharmaceuticals by Roche Holding AG. He also served on the board at Foundation Medicine, Inc., Chugai Pharmaceutical Co., Ltd., Genentech, Inc. and Roche Diagnostics GmbH. He received his undergraduate degree from Georgetown University and an MBA from The Trustees of Columbia University in The City of New York.


Current positions of Daniel O'Day 
Holdings of Daniel O'Day 
Daniel O'Day : Personal Network 
Most Read News 
07/12ELON MUSK : Musk tells SolarCity trial that Tesla would 'die' if he wasn't CEO
RE
07/15JAMIE DIMON : Analysis-JPMorgan hoards cash as Dimon expects rates to rise
RE
07/13RICHARD BRANSON : Virgin Galactic acknowledges Branson's pre-launch bike ride never happened
RE
07/20JEFF BEZOS : billionaire Bezos has successful suborbital jaunt
RE
07/13ELON MUSK : Musk defends timing of Tesla's $2.6 billion deal for SolarCity
RE
07/09ELON MUSK : Who controls Tesla?
RE
07/13BRUNELLO CUCINELLI : Italian luxury group Cucinelli raises 2021 sales forecast again
RE
07/22RYAN COHEN : Flush from Reddit rally, GameStop plots store revival
RE
07/18ALEXANDER NOVAK : Novak says Russia to raise oil output in H2
RE
07/20WILLIAM ACKMAN : Analysis-SPAC u-turn mars Ackman's hedge fund pivot
RE
More news


© 2021 People and Ownership :   
Daniel O'Day : Connections 


Latest news about Daniel O'Day 
02/04GILEAD SCIENCES : Sells $1.94 Billion In Covid-19 Treatment, Bolstering 4Q Performance
DJ
01/11Gilead Lifts Guidance as Remdesivir Sales Surge; CEO Expects Treatment to Be Effective Against New Coronavirus Strains
MT
2020GILEAD SCIENCES : to acquire German biotech firm MYR for about 1.15 billion euros
RE
2020GILEAD SCIENCES : to Pay $1.4 Billion for Hepatitis Drug Maker MYR GmbH of Germany
DJ
2020Gilead Quarterly Revenue Rises on Remdesivir Sales -- Update
DJ
2020GILEAD SCIENCES : Quarterly Revenue Rises on Remdesivir Sales
DJ
2020Covid-19 Drug Remdesivir Fully Approved by FDA
DJ
More news